PicRasidine I has antiosteoclastogenic effect by inhibiting inflammation induced activation of MAPKs, NF-?oB and ROS generation followed by suppressing the gene expression of c-Fos and NFATc1 in osteoclast precursors.

Picrasidine I has antiosteoclastogenic effect by inhibiting inflammation induced activation of MAPKs, NF-IoB and ROS generation followed by suppressing the gene expression of c-Fos and NFATc1 in osteoclast precursors.

100234-59-1

C14H12N2O2

240.26

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years